Outcomes of HeartMate 3 in pediatric patients with end-stage heart failure: a single-center preliminary experience from Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-0340-7741
dc.authorid0003-4708-0442
dc.authorid0000-0001-6495-1639
dc.authorid0000-0002-6288-7992
dc.authorid0000-0003-4776-2478
dc.authorid0000-0001-6282-2489
dc.authorid0000-0002-5717-0057
dc.authorid0000-0003-0259-0799
dc.contributor.authorDogan, Eser
dc.contributor.authorUlger Tutar, Zulal
dc.contributor.authorTuncer, Osman Nuri
dc.contributor.authorLevent, Resit E.
dc.contributor.authorEngin, Cagatay
dc.contributor.authorYagdi, Tahir
dc.contributor.authorAtay, Yuksel
dc.contributor.authorOzbaran, Mustafa
dc.date.accessioned2025-04-18T11:03:47Z
dc.date.available2025-04-18T11:03:47Z
dc.date.issued2024
dc.departmentEge Üniversitesi, Tıp Fakültesi, Dahili Bilimler Bölümü, Kardiyoloji Ana Bilim Dalı
dc.description.abstractObjectives We aim to evaluate our initial experience with the HeartMate 3 (HM3) device (Abbott, USA) for palliating pediatric patients with end-stage heart failure (ESHF).Methods We conducted a retrospective review of clinical data from pediatric patients (aged 7-18 years) who underwent HM3 implantation for ESHF at our institution between 2022 and 2024. Patient demographics and follow-up data were comprehensively analyzed.Results We identified 11 patients (45% males) with a median age of 14 years (IQR 11-17), a median weight of 47 kg (IQR 28-50), a median height of 159 cm (IQR 135-165), and a median body surface area of 1.36 m2 (IQR 1.07-1.53) at the time of the intervention. All patients were diagnosed with dilated cardiomyopathy and categorized with PEDIMACS profiles ranging from one to three. The median ICU stay was 14 days (IQR 6-32), with 11 patients receiving inotropic support for a median of four postoperative days (IQR 3-8). The median follow-up period was 150 days (IQR 90-210). Early complications included two cases of pleural effusion, 1 case of cardiac tamponade, 3 cases of polyuria, and one instance of positive blood cultures. One patient, who was non-compliant with warfarin therapy, developed a thrombus in the right atrium that was resolved with a revision of anticoagulant therapy, and did not experience pump thrombosis. During follow-up, one patient died after 28 days from sepsis, one underwent heart transplantation after 10 days, and nine patients remained alive on the device. Notably, there were no reported cases of pump thrombosis, ischemia, or stroke post- implantation.Conclusions The HM3 device appears to be a safe and effective palliative option for pediatric patients with ESHF.
dc.identifier.citationDogan, E., Tutar, Z. U., Tuncer, O. N., Levent, R. E., Engin, C., Yagdi, T., Atay, Y., & Ozbaran, M. (2024). Outcomes of HeartMate 3 in pediatric patients with end-stage heart failure: A single-center preliminary experience from turkey. Frontiers in Cardiovascular Medicine, 11.
dc.identifier.doi10.3389/fcvm.2024.1472663
dc.identifier.endpage7
dc.identifier.issn2297055X
dc.identifier.issueOct
dc.identifier.pmid39469126
dc.identifier.scopus2-s2.0-85207471622
dc.identifier.scopusqualityQ2
dc.identifier.startpage1
dc.identifier.urihttps://doi.org/10.3389/fcvm.2024.1472663
dc.identifier.urihttps://hdl.handle.net/11454/117120
dc.identifier.volume11
dc.identifier.wosWOS:001342314200001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorDogan, Eser
dc.institutionauthorUlger Tutar, Zulal
dc.institutionauthorTuncer, Osman Nuri
dc.institutionauthorLevent, Resit E.
dc.institutionauthorEngin, Cagatay
dc.institutionauthorYagdi, Tahir
dc.institutionauthorAtay, Yuksel
dc.institutionauthorOzbaran, Mustafa
dc.institutionauthorid0000-0002-0340-7741
dc.institutionauthorid0003-4708-0442
dc.institutionauthorid0000-0001-6495-1639
dc.institutionauthorid0000-0002-6288-7992
dc.institutionauthorid0000-0003-4776-2478
dc.institutionauthorid0000-0001-6282-2489
dc.institutionauthorid0000-0002-5717-0057
dc.institutionauthorid0000-0003-0259-0799
dc.language.isoen
dc.publisherFrontiers Media SA
dc.relation.ispartofFrontiers in Cardiovascular Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectcardiac transplant
dc.subjectheart failure
dc.subjectHeartMate 3
dc.subjectpediatric
dc.subjectTurkey
dc.titleOutcomes of HeartMate 3 in pediatric patients with end-stage heart failure: a single-center preliminary experience from Turkey
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu